Cell-based Therapy to Improve Muscle Strength to Get Clinical Trial
Cabaletta Bio has been cleared by the U.S. Food and Drug Administration (FDA) to start first-in-human clinical testing of…
Articles by Marisa Wexler, MS
Study Estimates Risks of MG-related Problems During Pregnancy at 34%
The risk of myasthenia gravis (MG) worsening during pregnancy is about 34%, a new study estimates. Notably, most…
Model of Neuromuscular Junction May Help Evaluate MG Treatments
Scientists described a new cellular model of the neuromuscular junction that could be useful for diagnosing myasthenia gravis (MG)…
PRO Tool May Better Address MG Symptoms Most Affecting Patients
By analyzing available research and conducting nearly 100 interviews with patients, an international team of researchers crafted a new tool…
Argenx Gears Up for US Launch of Vyvgart, Awaiting EU Decision
Argenx is working toward the commercial launch of Vyvgart (efgartigimod) — recently approved by the U.S. Food and…
Top 10 Myasthenia Gravis Stories of 2021
Throughout 2021, Myasthenia Gravis News has brought you coverage on the latest scientific advancements and clinical trials related to myasthenia…
Case Report Highlights Rare Form of MG Affecting Newborns
Infants born to women with myasthenia gravis (MG) may develop a rare condition called transient neonatal myasthenia gravis…
Ultomiris Rapidly Eases Symptoms of Generalized MG in Phase 3 Trial
Treatment with Ultomiris (ravulizumab-cwvz), a complement-blocking therapy, quickly eased symptom severity in adults with generalized myasthenia gravis (gMG), according…
FDA Approves Vyvgart for Adults With Most Common Form of gMG
Vyvgart (efgartigimod) has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with generalized myasthenia gravis…
‘Human-on-a-Chip’ Disease Model Can Potentially Test Therapies Better
“Human-on-a-chip” technology developed by Hesperos can be used to model myasthenia gravis (MG), a new study shows. “This…